Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis

被引:10
|
作者
Ayenew, Wondim [1 ]
Asmamaw, Getahun [2 ]
Bitew, Teshome [3 ]
机构
[1] Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Pharmaceut, POB 196, Gondar, Ethiopia
[2] Arba Minch Univ, Coll Med & Hlth Sci, Dept Pharm, Arba Minch, Ethiopia
[3] Pawe Hlth Sci Coll, Dept Pharm, Pawe, Ethiopia
来源
关键词
Africa; antipsychotic polypharmacy; antipsychotic prescribing; correlates of antipsychotic polypharmacy; prevalence; LONG-ACTING INJECTIONS; PSYCHIATRIC-PATIENTS; PREVALENCE; ADOLESCENTS; OUTPATIENTS; CHILDREN; 2ND-GENERATION; PRESCRIPTION; TRENDS; DRUGS;
D O I
10.1093/ijnp/pyab046
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: In Africa, antipsychotic polypharmacy (APP) is increasing due to a high antipsychotic dose prescribing, repeated psychiatric hospitalization, uncontrolled psychotic symptoms, and greater side effect burden. Therefore, the aim of this review and meta-analysis is to assess the prevalence and correlates of APP among patients with schizophrenia in Africa. Methods: A systematic search was performed from August 1 to 31, 2020, on PubMed, MEDLINE, Google Scholar, and Science Direct databases to select articles based on the inclusion criteria. Meta-Analysis of Observational studies in Epidemiology guidelines were employed. Cross-sectional observational studies that reported APP and/or its correlates in schizophrenia patients in English language published in peer-reviewed journals without time limits were included in the review. The quality of included articles was assessed using Newcastle-Ottawa quality assessment tool. Prevalence and correlates of APP were the outcome measures of this review and meta-analysis. Open Meta Analyst and RevMan version 5.3 software were used for meta-analysis. A random effect model was used to synthesize data based on the heterogeneity test. Results: Six studies that involved 2154 schizophrenia patients met the inclusion criteria in this review and meta-analysis. The quality of included studies ranges from 6.5 to 10 based on the Newcastle-Ottawa quality assessment tool. The pooled prevalence of APP among patients with schizophrenia was 40.6% with 95% confidence interval: 27.6% to 53.7%. Depot first-generation antipsychotics and oral first-generation antipsychotics were the most commonly prescribed APP combinations. Socio-demographic, clinical, and antipsychotic treatment characteristics were significantly associated with APP. There was a wide variation in the correlates of APP assessed by studies and the way that association/correlations was determined and reported. Conclusions: APP is common and highly prevalent. Advanced age, male gender, longer duration of schizophrenia, hospital admission, and longer antipsychotic treatment were correlates of APP in Africa.
引用
收藏
页码:956 / 964
页数:9
相关论文
共 50 条
  • [1] Antipsychotic polypharmacy in schizophrenia: results from a systematic review and meta-analysis of augmentation with a second antipsychotic
    Galling, B.
    Roldan, A.
    Correll, C. U.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S499 - S499
  • [2] Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis
    Matsui, Kentaro
    Tokumasu, Takahiro
    Takekita, Yoshiteru
    Inada, Ken
    Kanazawa, Tetsufumi
    Kishimoto, Taishiro
    Takasu, Shotaro
    Tani, Hideaki
    Tarutani, Seiichiro
    Hashimoto, Naoki
    Yamada, Hiroki
    Yamanouchi, Yoshio
    Takeuchi, Hiroyoshi
    SCHIZOPHRENIA RESEARCH, 2019, 209 : 50 - 57
  • [3] Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis
    Krause, Marc
    Huhn, Maximilian
    Schneider-Thoma, Johannes
    Rothe, Philipp
    Smith, Robert C.
    Leucht, Stefan
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (12) : 1360 - 1370
  • [4] Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis
    Vayisoglu, Sefa
    Karahan, Sevilay
    Anil Yagcioglu, A. Elif
    TURK PSIKIYATRI DERGISI, 2019, 30 (04) : 253 - 259
  • [5] Polypharmacy in Patients with CKD A Systematic Review and Meta-Analysis
    Oosting, Ilse J.
    Colombijn, Julia M. T.
    Kaasenbrood, Lotte
    Liabeuf, Sophie
    Laville, Solene M.
    Hooft, Lotty
    Bots, Michiel L.
    Verhaar, Marianne C.
    Vernooij, Robin W. M.
    KIDNEY360, 2024, 5 (06): : 841 - 850
  • [6] The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis
    Leucht, Stefan
    Chaimani, Anna
    Krause, Marc
    Schneider-Thoma, Johannes
    Wang, Dongfang
    Dong, Shimeng
    Samara, Myrto
    Peter, Natalie
    Huhn, Maximilian
    Priller, Josef
    Davis, John M.
    LANCET PSYCHIATRY, 2022, 9 (11): : 884 - 893
  • [7] POLYPHARMACY TO COUNTERACT ANTIPSYCHOTIC-INDUCED WEIGHT GAIN AND METABOLIC ADVERSE EFFECTS IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Mizuno, Yuya
    Suzuki, Takefumi
    Nakagawa, Atsuo
    Yoshida, Kazunari
    Mimura, Masaru
    Fleischhacker, W. Wolfgang
    Uchida, Hiroyuki
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S91 - S91
  • [8] Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
    Bennekom, Marc W. H. Lochmann van
    Inthout, Joanna
    Gijsman, Harm J.
    Akdede, Berna B. K.
    Yagcioglu, Elif Anil
    Barnes, Thomas R. E.
    Galling, Britta
    Gueorguieva, Ralitza
    Kasper, Siegfried
    Kreinin, Anatoly
    Nielsen, Jimmi
    Nielsen, Rene Ernst
    Remington, Gary
    Repo-Tiihonen, Eila
    Schmidt-Kraepelin, Christian
    Shafti, Saeed S.
    Xiao, Le
    Correll, Christoph U.
    Verkes, Robbert-Jan
    SCHIZOPHRENIA RESEARCH, 2024, 272 : 1 - 11
  • [9] Psychosis and schizophrenia among patients with epilepsy: A systematic review and meta-analysis
    Thapa, Sangharsha
    Panah, Mohammad Yazdan
    Vaheb, Saeed
    Dahal, Krishna
    Maharjan, Prashanna Man
    Shah, Sangam
    Mirmosayyeb, Omid
    EPILEPSY RESEARCH, 2024, 207
  • [10] Antipsychotic Trials in Schizophrenia from India: A Systematic Review and Meta-analysis
    Grover, S.
    Sarkar, S.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 (06) : 771 - 779